Navigation Links
MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
Date:9/29/2010

MOUNTAIN VIEW, Calif., Sept. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the pricing of its underwritten registered offering of 3,000,000 shares of its common stock at an offering price of $14.50 per share.  Net offering proceeds, after estimated underwriting discounts and commissions and other estimated offering expenses, will be approximately $40.9 million, assuming no exercise by the underwriters of their over-allotment option.  MAP Pharmaceuticals has granted the underwriters of the offering a thirty (30) day option to purchase up to 450,000 additional shares to cover over-allotments, if any.  MAP Pharmaceuticals intends to use the proceeds from this offering for the development of LEVADEX and for general corporate purposes.  MAP Pharmaceuticals expects the offering to close on or about October 4, 2010, subject to customary closing conditions.  Lazard Capital Markets LLC is acting as the sole book-running manager and Wedbush PacGrow Life Sciences as the co-manager for the offering.

MAP Pharmaceuticals has filed a shelf registration statement on Form S-3 and an accompanying prospectus with the Securities and Exchange Commission ("SEC"), which was declared effective by the SEC.  A prospectus supplement describing the terms of the offering will be filed with the SEC and will form a part of the effective registration statement.  When available, copies of the preliminary prospectus supplement, the final prospectus supplement and accompanying base prospectus related to this offering may be obtained from the SEC's website at http://www.sec.gov or Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020 or via telephone at (800) 542-0970.

This press release shall not constitute an offer to sell or the solicitation of o
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014  Formex, LLC ("Formex"), a leader in ... Weilersbacher joined Formex as Director of Quality ... Greg Weilersbacher has over 20 ... in Quality Assurance, Facility Validation, GMP manufacturing, and ... to Formex a diverse wealth of experience. ...
(Date:9/16/2014)... 2014 On September 25 to 26, 2014, ... medical design and manufacturing - MEDTEC China  - will ... Exhibition & Convention Center, bringing together close to 300 ... showcase their latest medical-grade raw materials, parts and processing ... remaining for free visitor pre-registration to be completed. To ...
(Date:9/16/2014)... 16, 2014 CorMedix Inc. ("CorMedix") (NYSE ... and commercializing therapeutic products for the prevention and ... the amendment and restatement of its outstanding Series ... related warrants, as well as the warrants issued ... financing, to remove anti-dilution, price reset and certain ...
Breaking Medicine Technology:Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
... , , STAMFORD, ... Zargis Medical, a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE ... New Product Awards on February 11th—the 163rd birthday of renowned inventor ... in New York City . Edison created many of the ...
... Rowinsky to Serve on RRD International,s Product Advisory ... 17 RRD International, a strategy-driven biotech and ... Rowinsky , M.D. will oversee oncology product development, serving ...  Dr. Rowinsky is a highly accomplished cancer therapeutics expert ...
Cached Medicine Technology:Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 2Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 3Cancer Expert Dr. Eric Rowinsky to Oversee Oncology Product Development at RRD International 2Cancer Expert Dr. Eric Rowinsky to Oversee Oncology Product Development at RRD International 3
(Date:9/16/2014)... 2014 The second federal bellwether trial ... Johnson subsidiary Ethicon concluded with the jury in the ... awarding her $3.27 million in damages, according to a ... “jurors found Ethicon liable for selling faulty devices and ... were at risk from side effects that include pain, ...
(Date:9/16/2014)... 16, 2014 Advanced Fertility Center of ... by Houstonia Magazine as one of the Top Doctors ... Magazine - a metropolitan magazine serving the Houston area. ... recognize them for their outstanding services. This accomplishment will ... of Houstonia Magazine — a special publication listing all ...
(Date:9/16/2014)... Duke’s Chowder House Lake Union is ... and Gratafy for a fun evening of tech networking. ... cemented. With the growth of companies in these sectors, there’s also ... work in tech and at startups to connect with each other. ... to host events for their peers to meet and mingle in ...
(Date:9/16/2014)... radiation therapy as part of breast conservation is ... hormone-receptor positive (HR+) invasive breast cancer. A new ... however, shows that combination may not be necessary ... , The results, which Fox Chase researchers presented ... Annual Meeting on Sunday, September 14, suggest that ...
(Date:9/16/2014)... This year’s theme is centered around entrepreneurism ... Mills, Pennsylvania, September 15, 2014- Holganix, an elite member ... growing companies in the country, produces an organic Bionutritional ... health-care by naturally decreasing disease and insect damage though ... that it will hold its third annual Bionutritional Summit ...
Breaking Medicine News(10 mins):Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... Steven Reinberg HealthDay Reporter , MONDAY, March ... second of three reactors at earthquake-ravaged Japan,s Fukushima Dai-ichi ... the facility were safe, according to news reports. ... with seawater after Friday,s devastating earthquake and tsunami knocked ...
... major study of the wellbeing and inclusion of former ... by Queen,s University today (Monday 14 March). ... in Northern Ireland and the border region of Ireland ... of loyalist and republican former prisoners (aged 50 and ...
... Researchers at Georgia Health Sciences University are studying whether ... metabolite could halt the progression of diabetic nephropathy, or ... year, $308,000 grant from the American Heart Association, Dr. ... College of Dental Medicine and Pharmacology and Toxicology in ...
... International Liver CongressTM is an opportunity for over ... to hear the latest research, perspectives and treatments ... field. It features a high-calibre and multi-disciplinary scientific ... the most essential topics. EASL will hold ...
... taken by certain women as a preventive measure against breast ... conclusion of a new study published early online in ... The study,s results suggest that the benefits of tamoxifen to ... post-menopausal women under age 55 years who have an increased ...
... to resist the targeted drug Herceptin, but a single ... vulnerability to treatment, scientists at The University of Texas ... Nature Medicine . Adding the drug saracatinib to ... at least five different molecular pathways, each of which ...
Cached Medicine News:Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 2Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 3Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 4Health News:Report into well-being and inclusion of former politically motivated prisoners 2Health News:Report into well-being and inclusion of former politically motivated prisoners 3Health News:International Liver Congress 2011 2Health News:Taking tamoxifen to prevent breast cancer can save lives and money 2Health News:Combination overcomes breast cancer resistance to herceptin 2Health News:Combination overcomes breast cancer resistance to herceptin 3
... Digisonics is a web-based application to securely ... cardiovascular modalities. Users can login from ... password to review stored patient studies. ... patient information, images, and reports Quickly locates ...
... stands for Stainless Steel Kleener. SSK-80 is ... and stain remover for ultra-sonic cleaners. , ... of your instruments by removing and inhibiting ... pivot points, box joints and moving instrument ...
... Foam is the ready-to-use, pre-cleaning enzymatic foam ... ,Hemaway Enzymatic Foam sprays on ... It's perfect for use in the O.R. ... Getting a head start with Hemaway Enzymatic ...
... Cytospin has been synonymous with ... More than 15,000 laboratories worldwide ... It provides economical thin-layer preparations ... hypocellular fluids such as spinal ...
Medicine Products: